Company: DAWN
Filing Date: 2025-03-06
Form Type: 10-K/A
Source: 0000950170-25-034878
Chunk: 42

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K/A
Chunk 42
---
    350 |   |
|:-----------------------------------------------------|:--|-------:|:--|
| 2026                                                 |   |    432 |   |
| 2027                                                 |   |    445 |   |
| 2028                                                 |   |    459 |   |
| 2029                                                 |   |    711 |   |
| Thereafter                                           |   |  1,981 |   |
| Total future minimum lease payments                  |   |  4,378 |   |
| Less: imputed interest                               |   | (1,776 | ) |
| Present value of operating lease liabilities         |   |  2,602 |   |
| Less: current portion of operating lease liabilities |   |    (10 | ) |
| Long-term portion of operating lease liabilities     | $ |  2,592 |   |

<div align='center'>F-27</div>

Research and Development Agreements The Company enters into contracts in the normal course of business with clinical research organizations, contract manufacturing organizations, and other third-party vendors for clinical trial, manufacturing, testing, and other research and development activities. These contracts generally provide for termination on notice, with the exception of one vendor where certain costs are non-cancellable after the approval of the project. As of December 31, 2024 and 2023 , there were no amounts accrued related to termination and cancellation charges as these are not probable. License Agreements The Company entered into license agreements, as disclosed in Note 5, with various parties under which it is obligated to make contingent and non-contingent payments. Purchase Commitments To support product needs for OJEMDA, the Company has entered into a manufacturing and supply agreement with Quotient Sciences - Philadelphia, LLC in July 2023 that requires the Company to meet minimum purchase obligations on an annual basis. The remaining amount of future minimum purchase obligations under the manufacturing and supply agreement over the next five years is approximately $ 14.1 million, in aggregate, as of December 31, 2024. For the year ended December 31, 2024 , the Company has made $ 3.0 million of purchases under the purchase obligation. Legal Proceedings The Company, from time to time, may be party to litigation, claims and assessments arising in the ordinary course of business. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. The Company is not